Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

Differential Alterations in Metabolism and Proteolysis-Related Proteins in Human Parkinson's Disease Substantia Nigra.

Grünblatt E, Ruder J, Monoranu CM, Riederer P, Youdim MB, Mandel SA.

Neurotox Res. 2018 Apr;33(3):560-568. doi: 10.1007/s12640-017-9843-5. Epub 2017 Dec 7.

PMID:
29218503
2.

Minimally Invasive Transpalpebral Endoscopic-Assisted Amygdalohippocampectomy.

Mandel M, Figueiredo EG, Mandel SA, Tutihashi R, Teixeira MJ.

Oper Neurosurg (Hagerstown). 2017 Feb 1;13(1):2-14. doi: 10.1227/NEU.0000000000001179.

PMID:
28931250
3.

Minimally Invasive Transpalpebral ''Eyelid'' Approach to Unruptured Middle Cerebral Artery Aneurysms.

Mandel M, Tutihashi R, Mandel SA, Teixeira MJ, Figueiredo EG.

Oper Neurosurg (Hagerstown). 2017 Aug 1;13(4):453-464. doi: 10.1093/ons/opx021.

PMID:
28838124
4.

DJ-1 deficiency triggers microglia sensitivity to dopamine toward a pro-inflammatory phenotype that is attenuated by rasagiline.

Trudler D, Weinreb O, Mandel SA, Youdim MB, Frenkel D.

J Neurochem. 2014 May;129(3):434-47. doi: 10.1111/jnc.12633. Epub 2014 Jan 6.

5.

In the rush for green gold: Can green tea delay age-progressive brain neurodegeneration?

Mandel SA, Youdim MB.

Recent Pat CNS Drug Discov. 2012 Dec;7(3):205-17. Review.

PMID:
22742421
6.

A molecular signature in blood identifies early Parkinson's disease.

Molochnikov L, Rabey JM, Dobronevsky E, Bonucelli U, Ceravolo R, Frosini D, Grünblatt E, Riederer P, Jacob C, Aharon-Peretz J, Bashenko Y, Youdim MB, Mandel SA.

Mol Neurodegener. 2012 May 31;7:26. doi: 10.1186/1750-1326-7-26.

7.

Effects of novel neuroprotective and neurorestorative multifunctional drugs on iron chelation and glucose metabolism.

Pollak Y, Mechlovich D, Amit T, Bar-Am O, Manov I, Mandel SA, Weinreb O, Meyron-Holtz EG, Iancu TC, Youdim MB.

J Neural Transm (Vienna). 2013 Jan;120(1):37-48. doi: 10.1007/s00702-012-0795-x. Epub 2012 Mar 25.

PMID:
22446839
8.

From anti-Parkinson's drug rasagiline to novel multitarget iron chelators with acetylcholinesterase and monoamine oxidase inhibitory and neuroprotective properties for Alzheimer's disease.

Zheng H, Amit T, Bar-Am O, Fridkin M, Youdim MB, Mandel SA.

J Alzheimers Dis. 2012;30(1):1-16. doi: 10.3233/JAD-2012-120013. Review.

PMID:
22387411
9.

Targeting SKP1, an ubiquitin E3 ligase component found decreased in sporadic Parkinson's disease.

Mandel SA, Fishman-Jacob T, Youdim MB.

Neurodegener Dis. 2012;10(1-4):220-3. doi: 10.1159/000333223. Epub 2011 Dec 23. Review.

PMID:
22205206
10.

Molecular mechanisms of the neuroprotective/neurorescue action of multi-target green tea polyphenols.

Mandel SA, Weinreb O, Amit T, Youdim MB.

Front Biosci (Schol Ed). 2012 Jan 1;4:581-98. Review.

PMID:
22202078
11.

Genetic reduction of the E3 ubiquitin ligase element, SKP1A and environmental manipulation to emulate cardinal features of Parkinson's disease.

Mandel SA, Fishman-Jacob T, Youdim MB.

Parkinsonism Relat Disord. 2012 Jan;18 Suppl 1:S177-9. doi: 10.1016/S1353-8020(11)70055-4.

PMID:
22166427
12.

Neuroprotective profile of the multitarget drug rasagiline in Parkinson's disease.

Weinreb O, Amit T, Riederer P, Youdim MB, Mandel SA.

Int Rev Neurobiol. 2011;100:127-49. doi: 10.1016/B978-0-12-386467-3.00007-8. Review.

PMID:
21971006
13.

Understanding the broad-spectrum neuroprotective action profile of green tea polyphenols in aging and neurodegenerative diseases.

Mandel SA, Amit T, Weinreb O, Youdim MB.

J Alzheimers Dis. 2011;25(2):187-208. doi: 10.3233/JAD-2011-101803. Review.

PMID:
21368374
14.

PGC-1α, a potential therapeutic target for early intervention in Parkinson's disease.

Zheng B, Liao Z, Locascio JJ, Lesniak KA, Roderick SS, Watt ML, Eklund AC, Zhang-James Y, Kim PD, Hauser MA, Grünblatt E, Moran LB, Mandel SA, Riederer P, Miller RM, Federoff HJ, Wüllner U, Papapetropoulos S, Youdim MB, Cantuti-Castelvetri I, Young AB, Vance JM, Davis RL, Hedreen JC, Adler CH, Beach TG, Graeber MB, Middleton FA, Rochet JC, Scherzer CR; Global PD Gene Expression (GPEX) Consortium.

Sci Transl Med. 2010 Oct 6;2(52):52ra73. doi: 10.1126/scitranslmed.3001059.

15.

Biomarkers for prediction and targeted prevention of Alzheimer's and Parkinson's diseases: evaluation of drug clinical efficacy.

Mandel SA, Morelli M, Halperin I, Korczyn AD.

EPMA J. 2010 Jun;1(2):273-92. doi: 10.1007/s13167-010-0036-z. Epub 2010 Jun 29.

16.

The novel multifunctional, iron-chelating drugs M30 and HLA20 protect pancreatic beta-cell lines from oxidative stress damage.

Mechlovich D, Amit T, Mandel SA, Bar-Am O, Bloch K, Vardi P, Youdim MB.

J Pharmacol Exp Ther. 2010 Jun;333(3):874-82. doi: 10.1124/jpet.109.164269. Epub 2010 Mar 17.

PMID:
20237072
17.

Low dosage of rasagiline and epigallocatechin gallate synergistically restored the nigrostriatal axis in MPTP-induced parkinsonism.

Reznichenko L, Kalfon L, Amit T, Youdim MB, Mandel SA.

Neurodegener Dis. 2010;7(4):219-31. doi: 10.1159/000265946. Epub 2010 Feb 27.

PMID:
20197647
18.

Silencing/overexpressing selected genes as a model of sporadic Parkinson's disease.

Fishman-Jacob T, Youdim MB, Mandel SA.

Neurodegener Dis. 2010;7(1-3):108-11. doi: 10.1159/000285517. Epub 2010 Feb 18.

PMID:
20173338
19.

Modeling sporadic Parkinson's disease by silencing the ubiquitin E3 ligase component, SKP1A.

Mandel SA, Fishman-Jacob T, Youdim MB.

Parkinsonism Relat Disord. 2009 Dec;15 Suppl 3:S148-51. doi: 10.1016/S1353-8020(09)70803-X. Review.

PMID:
20082978
20.

A sporadic Parkinson disease model via silencing of the ubiquitin-proteasome/E3 ligase component SKP1A.

Fishman-Jacob T, Reznichenko L, Youdim MB, Mandel SA.

J Biol Chem. 2009 Nov 20;284(47):32835-45. doi: 10.1074/jbc.M109.034223. Epub 2009 Sep 11.

21.

Biomarkers for evaluation of clinical efficacy of multipotential neuroprotective drugs for Alzheimer's and Parkinson's diseases.

Halperin I, Morelli M, Korczyn AD, Youdim MB, Mandel SA.

Neurotherapeutics. 2009 Jan;6(1):128-40. doi: 10.1016/j.nurt.2008.10.033. Review.

22.

Simultaneous manipulation of multiple brain targets by green tea catechins: a potential neuroprotective strategy for Alzheimer and Parkinson diseases.

Mandel SA, Amit T, Weinreb O, Reznichenko L, Youdim MB.

CNS Neurosci Ther. 2008 Winter;14(4):352-65. doi: 10.1111/j.1755-5949.2008.00060.x. Review.

PMID:
19040558
23.

Gene and protein signatures in sporadic Parkinson's disease and a novel genetic model of PD.

Mandel SA, Fishman T, Youdim MB.

Parkinsonism Relat Disord. 2007;13 Suppl 3:S242-7. doi: 10.1016/S1353-8020(08)70009-9. Review.

PMID:
18267243
24.

Cell signaling pathways and iron chelation in the neurorestorative activity of green tea polyphenols: special reference to epigallocatechin gallate (EGCG).

Mandel SA, Amit T, Kalfon L, Reznichenko L, Weinreb O, Youdim MB.

J Alzheimers Dis. 2008 Oct;15(2):211-22. Review.

PMID:
18953110
25.

Targeting multiple neurodegenerative diseases etiologies with multimodal-acting green tea catechins.

Mandel SA, Amit T, Kalfon L, Reznichenko L, Youdim MB.

J Nutr. 2008 Aug;138(8):1578S-1583S.

PMID:
18641210
26.
29.

Multifunctional activities of green tea catechins in neuroprotection. Modulation of cell survival genes, iron-dependent oxidative stress and PKC signaling pathway.

Mandel SA, Avramovich-Tirosh Y, Reznichenko L, Zheng H, Weinreb O, Amit T, Youdim MB.

Neurosignals. 2005;14(1-2):46-60. Review.

30.

Familial resemblance for glucose and insulin metabolism indices derived from an intravenous glucose tolerance test in Blacks and Whites of the HERITAGE Family Study.

Hong Y, Weisnagel SJ, Rice T, Sun G, Mandel SA, Gu C, Rankinen T, Gagnon J, Leon AS, Skinner JS, Wilmore JH, Bergman RN, Bouchard C, Rao DC; HERITAGE Family Study.

Clin Genet. 2001 Jul;60(1):22-30.

PMID:
11531966
31.

Screening for colorectal cancer.

Ault MJ, Mandel SA.

N Engl J Med. 2000 Nov 30;343(22):1652; author reply 1652-4. No abstract available.

PMID:
11184983
32.

Senile dementia of the Alzheimer's type: an important risk factor for serious falls.

Morris JC, Rubin EH, Morris EJ, Mandel SA.

J Gerontol. 1987 Jul;42(4):412-7.

PMID:
3598089
33.

Race, socioeconomic status, and prostatic cancer.

Ernster VL, Winkelstein W Jr, Selvin S, Brown SM, Sacks ST, Austin DF, Mandel SA, Bertolli TA.

Cancer Treat Rep. 1977 Mar-Apr;61(2):187-91.

PMID:
872129

Supplemental Content

Loading ...
Support Center